Building Capabilities Today That Enable Tomorrow In A Capital-Constrained Environment

Chair

Sven Kili, Chief Development Officer, CCRM & OmniaBio

3pm Presentation: Start with How – Assuring Supply of Cell Therapies In Today’s Complex Economic Environment

• Review of current economic conditions and their impact on companies developing new therapies
• Approaches to assure supply and enable corporate strategy while balancing risk and cost
• Decision frameworks for building capabilities to meet your specific company’s needs

Aaron Vernon, Chief Manufacturing Officer, Quell Therapeutics

3.15pm Fireside Chat: The End of “Buy vs. Build” Analyses in Manufacturing, Making Way for Hybrid Approaches and Better COGS

J. Kelly Ganjei, President & Chief Executive Officer, Amplify Bio

3.30pm Presentation: From Gene to LNP: Nucleic Acid Research and Proprietary Manufacturing Technologies of WACKER BIOTECH

• Proprietary pDNA technologies
• State-of-the-art mRNA manufacturing and LNP formulation
• R&D to GMP Supply at WACKER BIOTECH

Mack Kuo, Associate Director of Process Development, Wacker